No headlines found.
PRNewswire (Tue, 14-May 8:30 AM ET)
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
PRNewswire (Wed, 8-May 4:01 PM ET)
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
PRNewswire (Wed, 24-Apr 4:05 PM ET)
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
PRNewswire (Tue, 27-Feb 6:54 PM ET)
PRNewswire (Thu, 22-Feb 4:01 PM ET)
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Dynavax Technologies trades on the NASDAQ stock market under the symbol DVAX.
As of May 21, 2024, DVAX stock price climbed to $11.46 with 1,113,064 million shares trading.
DVAX has a beta of 0.21, meaning it tends to be less sensitive to market movements. DVAX has a correlation of 0.01 to the broad based SPY ETF.
DVAX has a market cap of $1.50 billion. This is considered a Small Cap stock.
Last quarter Dynavax Technologies reported $51 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.05.
In the last 3 years, DVAX stock traded as high as $21.39 and as low as $7.26.
The top ETF exchange traded funds that DVAX belongs to (by Net Assets): IJR, XBI, VTI, IWM, CALF.
DVAX has underperformed the market in the last year with a price return of +3.9% while the SPY ETF gained +28.5%. DVAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.7% and -1.5%, respectively, while the SPY returned +7.3% and +2.9%, respectively.
DVAX support price is $11.13 and resistance is $11.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DVAX stock will trade within this expected range on the day.